Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Total revenue increased 13 per cent, 22 per cent at constant exchange rates, (CER) 1, to SEK 6,175 M ...

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...

ZYNLONTA was generally well tolerated, with safety findings consistent with its existing clinical profile.